Tuesday, March 31, 2020 12:13:19 PM
Post from cmm3rd on investor village
Two of Amarin's legal options
Here are a few preliminary thoughts about some of Amarin's legal options.
Amarin has the right to move for a new trial, which if they do, I would expect this same judge would deny. If they do this, I would expect their purpose would be simply to extend (at most a few months) the legal timeline and thus potentially delay the generics’ ultimate ability to launch a generic product.
They also have the right to appeal the judgment to the US Court of Appeals for the Federal Circuit (CAFC), which hears appeals from US district court judgments in patent cases. It’s a near certainty imo that Amarin will do this. If they do, I would expect the generics to cross-appeal their having lost the infringement part of the case, as, if the trial court’s determination of obviousness is overturned, the generics could still salvage a win by also getting the court’s infringement finding reversed (to no infringement).
The above rights to appeal are absolute. CAFC would have to hear those appeals.
I have not completed my research, but I am pretty sure that, at least as of 2016 (the year a good law review article on the subject was published), the standard of review on appeal from the obviousness finding is “de novo,” which basically means that CAFC (3 judge panel) does not defer much to the trial court’s findings that underlie the ultimate obviousness decision. Instead, CAFC would rule on the case based on the evidence of record, giving the trial court's decision little or no presumption of correctness, reviewing the evidence as a trial court would, and reviewing underlying factual determinations, for “clear error.” This standard of review (if it applies, and so far I think it does, but I have not finished my research) would favor Amarin (vs other standards of review) because the reviewing court essentially puts themselves in the shoes of the trial court when reviewing the evidence, and if at least 2 of the 3 members of the panel think the trial judge committed “clear error” in her review of/findings from the evidence and which led to an improper result, they should reverse the decision. I think this avenue will be viewed by Amarin as one of its primary levers to pull.
The losing party at the CAFC panel then has a right to petition for review by the panel and for review by the entire en banc CAFC. Most such petitions are denied. Those that are granted rarely result in a major change in the panel's opinion, but such a change does occasionally occur.
Two of Amarin's legal options
Here are a few preliminary thoughts about some of Amarin's legal options.
Amarin has the right to move for a new trial, which if they do, I would expect this same judge would deny. If they do this, I would expect their purpose would be simply to extend (at most a few months) the legal timeline and thus potentially delay the generics’ ultimate ability to launch a generic product.
They also have the right to appeal the judgment to the US Court of Appeals for the Federal Circuit (CAFC), which hears appeals from US district court judgments in patent cases. It’s a near certainty imo that Amarin will do this. If they do, I would expect the generics to cross-appeal their having lost the infringement part of the case, as, if the trial court’s determination of obviousness is overturned, the generics could still salvage a win by also getting the court’s infringement finding reversed (to no infringement).
The above rights to appeal are absolute. CAFC would have to hear those appeals.
I have not completed my research, but I am pretty sure that, at least as of 2016 (the year a good law review article on the subject was published), the standard of review on appeal from the obviousness finding is “de novo,” which basically means that CAFC (3 judge panel) does not defer much to the trial court’s findings that underlie the ultimate obviousness decision. Instead, CAFC would rule on the case based on the evidence of record, giving the trial court's decision little or no presumption of correctness, reviewing the evidence as a trial court would, and reviewing underlying factual determinations, for “clear error.” This standard of review (if it applies, and so far I think it does, but I have not finished my research) would favor Amarin (vs other standards of review) because the reviewing court essentially puts themselves in the shoes of the trial court when reviewing the evidence, and if at least 2 of the 3 members of the panel think the trial judge committed “clear error” in her review of/findings from the evidence and which led to an improper result, they should reverse the decision. I think this avenue will be viewed by Amarin as one of its primary levers to pull.
The losing party at the CAFC panel then has a right to petition for review by the panel and for review by the entire en banc CAFC. Most such petitions are denied. Those that are granted rarely result in a major change in the panel's opinion, but such a change does occasionally occur.
Recent AMRN News
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients • GlobeNewswire Inc. • 11/09/2025 09:15:00 PM
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
